Cargando…
Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
BACKGROUND: Immune checkpoint inhibitors (ICIs) were approved to have a significant antitumor activity in various tumor types. In practice, some patients do not seem to benefit from ICIs but rather to have accelerating disease. The aim of this study was to evaluate hyperprogression in patients with...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637510/ https://www.ncbi.nlm.nih.gov/pubmed/31315610 http://dx.doi.org/10.1186/s12885-019-5921-9 |
_version_ | 1783436254000447488 |
---|---|
author | Ji, Zhi Peng, Zhi Gong, Jifang Zhang, Xiaotian Li, Jian Lu, Ming Lu, Zhihao Shen, Lin |
author_facet | Ji, Zhi Peng, Zhi Gong, Jifang Zhang, Xiaotian Li, Jian Lu, Ming Lu, Zhihao Shen, Lin |
author_sort | Ji, Zhi |
collection | PubMed |
description | BACKGROUND: Immune checkpoint inhibitors (ICIs) were approved to have a significant antitumor activity in various tumor types. In practice, some patients do not seem to benefit from ICIs but rather to have accelerating disease. The aim of this study was to evaluate hyperprogression in patients with malignant tumors of digestive system treated with ICIs. METHODS: Medical records from consecutive patients with malignant tumors of digestive system treated with ICIs in Peking University Cancer Hospital were retrospectively collected. Tumor growth kinetics (TGK) on immunotherapy and TGK pre-immunotherapy were collected and TGK ratio (TGKR) was calculated. Hyperprogression was defined as TGKR≥2. RESULTS: From August 2016 to May 2017, 25 evaluable patients were identified from 45 patients with malignant tumors of digestive system. Five patients were considered as having hyperprogression. Three of 5 were neuroendocrine carcinomas (NECs) and the other 2 were adenocarcinomas. Four of 5 were treated with programmed cell death ligand 1 (PD-L1) inhibitor, the other one was treated with PD-L1 inhibitor combined with cytotoxic T lymphocyte associated antigen-4 (CTLA-4) inhibitor. Pseudoprogression was observed in 2 patients. CONCLUSIONS: Hyperprogression was observed in a fraction of patients with malignant tumors of digestive system treated with ICIs. Further investigation is urgently needed. |
format | Online Article Text |
id | pubmed-6637510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66375102019-07-25 Hyperprogression after immunotherapy in patients with malignant tumors of digestive system Ji, Zhi Peng, Zhi Gong, Jifang Zhang, Xiaotian Li, Jian Lu, Ming Lu, Zhihao Shen, Lin BMC Cancer Research Article BACKGROUND: Immune checkpoint inhibitors (ICIs) were approved to have a significant antitumor activity in various tumor types. In practice, some patients do not seem to benefit from ICIs but rather to have accelerating disease. The aim of this study was to evaluate hyperprogression in patients with malignant tumors of digestive system treated with ICIs. METHODS: Medical records from consecutive patients with malignant tumors of digestive system treated with ICIs in Peking University Cancer Hospital were retrospectively collected. Tumor growth kinetics (TGK) on immunotherapy and TGK pre-immunotherapy were collected and TGK ratio (TGKR) was calculated. Hyperprogression was defined as TGKR≥2. RESULTS: From August 2016 to May 2017, 25 evaluable patients were identified from 45 patients with malignant tumors of digestive system. Five patients were considered as having hyperprogression. Three of 5 were neuroendocrine carcinomas (NECs) and the other 2 were adenocarcinomas. Four of 5 were treated with programmed cell death ligand 1 (PD-L1) inhibitor, the other one was treated with PD-L1 inhibitor combined with cytotoxic T lymphocyte associated antigen-4 (CTLA-4) inhibitor. Pseudoprogression was observed in 2 patients. CONCLUSIONS: Hyperprogression was observed in a fraction of patients with malignant tumors of digestive system treated with ICIs. Further investigation is urgently needed. BioMed Central 2019-07-17 /pmc/articles/PMC6637510/ /pubmed/31315610 http://dx.doi.org/10.1186/s12885-019-5921-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ji, Zhi Peng, Zhi Gong, Jifang Zhang, Xiaotian Li, Jian Lu, Ming Lu, Zhihao Shen, Lin Hyperprogression after immunotherapy in patients with malignant tumors of digestive system |
title | Hyperprogression after immunotherapy in patients with malignant tumors of digestive system |
title_full | Hyperprogression after immunotherapy in patients with malignant tumors of digestive system |
title_fullStr | Hyperprogression after immunotherapy in patients with malignant tumors of digestive system |
title_full_unstemmed | Hyperprogression after immunotherapy in patients with malignant tumors of digestive system |
title_short | Hyperprogression after immunotherapy in patients with malignant tumors of digestive system |
title_sort | hyperprogression after immunotherapy in patients with malignant tumors of digestive system |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637510/ https://www.ncbi.nlm.nih.gov/pubmed/31315610 http://dx.doi.org/10.1186/s12885-019-5921-9 |
work_keys_str_mv | AT jizhi hyperprogressionafterimmunotherapyinpatientswithmalignanttumorsofdigestivesystem AT pengzhi hyperprogressionafterimmunotherapyinpatientswithmalignanttumorsofdigestivesystem AT gongjifang hyperprogressionafterimmunotherapyinpatientswithmalignanttumorsofdigestivesystem AT zhangxiaotian hyperprogressionafterimmunotherapyinpatientswithmalignanttumorsofdigestivesystem AT lijian hyperprogressionafterimmunotherapyinpatientswithmalignanttumorsofdigestivesystem AT luming hyperprogressionafterimmunotherapyinpatientswithmalignanttumorsofdigestivesystem AT luzhihao hyperprogressionafterimmunotherapyinpatientswithmalignanttumorsofdigestivesystem AT shenlin hyperprogressionafterimmunotherapyinpatientswithmalignanttumorsofdigestivesystem |